The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|January 29, 2019
Fresenius Kabi Launches Leucovorin Calcium Injection, USP
Author(s)Pharmaceutical Technology Editors
This injection formulation of USP-grade leucovorin calcium is now available in the United States.
Advertisement
On Jan. 29, 2019, Fresenius Kabi, a health care company specializing in medicines and technologies for infusion, transfusion and clinical nutrition, launched Leucovorin Calcium Injection, USP, for treating toxicity and diminishing the effects of impaired methotrexate elimination. The product, which the company states is the first liquid formulation of leucovorin calcium, is immediately available in the United States.
Leucovorin calcium is also used as a rescue drug after high-dose methotrexate therapy in osteosarcoma, in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, and in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
The Leucovorin Calcium Injection, USP, product is available in 10 mg/mL single-use vials and in 100 mg/10 mL and 500 mg/50 mL strengths.
“At Fresenius Kabi we are dedicated to finding safe and affordable solutions for health care providers,” said John Ducker, president and CEO of Fresenius Kabi USA, in a company press release. “We are pleased to offer a version of Leucovorin Calcium Injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication.”
Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement